Pollen Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Pollen Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major pollen allergy markets are expected to exhibit a CAGR of 2.79% during 2024-2034.

The pollen allergy market has been comprehensively analyzed in IMARC's new report titled "Pollen Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pollen allergy, also known as allergic rhinitis or hay fever, refers to a common allergic reaction that occurs when a person's immune system overreacts to pollen from various plants, such as trees, grasses, and weeds. This triggers the production of histamine and other chemicals, leading to allergy symptoms. The severity of indications can vary from mild to serious, depending on the amount of pollen exposure. Individuals suffering from this ailment may experience sneezing, nasal congestion, runny nose, itchy or watery eyes, coughing, itching of the throat or ears, fatigue, headache, a reduced sense of taste or smell, etc. These symptoms can substantially affect a person's quality of life, interfering with sleep, work, and daily activities. The diagnosis of pollen allergy is typically based on a combination of the patient's clinical features, medical history, and physical examination. A blood workup is further recommended to measure the level of specific IgE antibodies produced in response to allergens. Additionally, the healthcare provider may also perform skin prick tests to determine the cause of underlying indications among patients.

The increasing cases of genetic predisposition, in which malfunctioning genes that influence barrier integrity are passed down from parents to their children, are primarily driving the pollen allergy market. In addition to this, the rising prevalence of autoimmune disorders and chronic illnesses, resulting in overactive or underactive immune responses among individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antihistamines, such as cetirizine, fexofenadine, loratadine, etc., since they provide symptom relief by blocking the effects of histamine, a chemical released during an allergic reaction, is further bolstering the market growth. Apart from this, the inflating application of nasal corticosteroids to decrease inflammation in the nasal passages and promote quality of life is acting as another significant growth-inducing factor. Additionally, the emerging popularity of sublingual immunotherapy for the treatment of the disease on account of its numerous advantages, like high convenience, improved adherence, and a favorable safety profile over traditional allergy shots, is expected to drive the pollen allergy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pollen allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pollen allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pollen allergy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pollen allergy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pollen allergy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pollen allergy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the pollen allergy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pollen allergy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pollen allergy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of pollen allergy across the seven major markets?
What is the number of prevalent cases (2018-2034) of pollen allergy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pollen allergy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pollen allergy across the seven major markets?
What is the size of the pollen allergy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pollen allergy?
What will be the growth rate of patients across the seven major markets?

Pollen Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pollen allergy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pollen allergy market?
What are the key regulatory events related to the pollen allergy market?
What is the structure of clinical trial landscape by status related to the pollen allergy market?
What is the structure of clinical trial landscape by phase related to the pollen allergy market?
What is the structure of clinical trial landscape by route of administration related to the pollen allergy market?